Payment overview · 2025
General Payments
$1,982.67
99 reported records · 16 companies
Healthcare provider profile · identity verified
Sherwin Batoon, M.D
Allopathic & Osteopathic Physicians|Internal Medicine|Geriatric Medicine · FLUSHING, NY · NPI 1609947191
Verified facts
What the public records show
CMS Open Payments records show Sherwin Batoon, M.D received $1,982.67 in general payments during 2025 across 99 reported records.
AstraZeneca Pharmaceuticals LP accounted for 24.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic, Paxlovid, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 308 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 190 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 153 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Paxlovid by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trulance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $492.99 | 24.9% | 24 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $366.87 | 18.5% | 16 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $192.36 | 9.7% | 10 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $167.39 | 8.4% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $149.40 | 7.5% | 10 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $145.03 | 7.3% | 10 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $102.74 | 5.2% | 4 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $66.67 | 3.4% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $64.80 | 3.3% | 3 | 2025 |
| Validus Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $59.72 | 3.0% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $50.99 | 2.6% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $40.00 | 2.0% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $25.47 | 1.3% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $23.67 | 1.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.17 | 0.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.40 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,982.67 | 99 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $275.07 | 12 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $275.07 | 12 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $247.12 | 13 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $240.50 | 11 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $192.36 | 10 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $167.39 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $149.40 | 10 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $149.40 | 10 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $145.03 | 10 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $102.74 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $91.80 | 4 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $66.67 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $64.80 | 3 | 2025 |
Source payment records
|
|||||
| RALDESY Normalized: raldesy |
Drug | Validus Pharmaceuticals LLC | $59.72 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $50.99 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $46.69 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $40.00 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $40.00 | 2 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $25.47 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $23.67 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $18.17 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 308 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 190 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 153 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 25 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 100 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 38 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
308 | 68 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
29 | 14 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
190 | 38 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
38 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
153 | 26 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
100 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
71 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
25 | 24 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1018 | 263 |
| Losartan Potassium | Losartan Potassium | 738 | 195 |
| Levothyroxine Sodium | Levothyroxine Sodium | 443 | 99 |
| Amlodipine Besylate | Amlodipine Besylate | 428 | 115 |
| Metformin Hcl | Metformin Hcl | 338 | 91 |
| Hydralazine Hcl | Hydralazine Hcl | 334 | 90 |
| Fluticasone Propionate | Fluticasone Propionate | 317 | 162 |
| Farxiga | Dapagliflozin Propanediol | 308 | 68 |
| Famotidine | Famotidine | 301 | 82 |
| Metoprolol Tartrate | Metoprolol Tartrate | 299 | 79 |
| Pantoprazole Sodium | Pantoprazole Sodium | 261 | 75 |
| Alendronate Sodium | Alendronate Sodium | 255 | 82 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 252 | 100 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 216 | 159 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 207 | 46 |
| Carvedilol | Carvedilol | 206 | 52 |
| Jardiance | Empagliflozin | 190 | 38 |
| Januvia | Sitagliptin Phosphate | 184 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 180 | 47 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 175 | 45 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 154 | 125 |
| Ozempic | Semaglutide | 153 | 26 |
| Celecoxib | Celecoxib | 146 | 76 |
| Fenofibrate | Fenofibrate | 141 | 29 |
| Lisinopril | Lisinopril | 139 | 25 |
| Doxycycline Hyclate | Doxycycline Hyclate | 129 | 102 |
| Tamsulosin Hcl | Tamsulosin Hcl | 125 | 37 |
| Enalapril Maleate | Enalapril Maleate | 122 | 32 |
| Glipizide Er | Glipizide | 120 | 30 |
| Montelukast Sodium | Montelukast Sodium | 119 | 39 |
| Omeprazole | Omeprazole | 118 | 34 |
| Simvastatin | Simvastatin | 118 | 32 |
| Ezetimibe | Ezetimibe | 114 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 113 | 39 |
| Allopurinol | Allopurinol | 112 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 108 | 30 |
| Fluocinonide | Fluocinonide | 108 | 76 |
| Diclofenac Sodium | Diclofenac Sodium | 105 | 45 |
| Lovastatin | Lovastatin | 104 | 24 |
| Rybelsus | Semaglutide | 100 | 22 |
| Gabapentin | Gabapentin | 99 | 25 |
| Folic Acid | Folic Acid | 98 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 97 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 80 | 14 |
| Glipizide | Glipizide | 79 | 18 |
| Clonidine Hcl | Clonidine Hcl | 78 | 24 |
| Vascepa | Icosapent Ethyl | 78 | 20 |
| Furosemide | Furosemide | 76 | 27 |
| Valsartan | Valsartan | 74 | 20 |
| Ammonium Lactate | Ammonium Lactate | 73 | 27 |
| Meclizine Hcl | Meclizine Hcl | 72 | 33 |
| Eliquis | Apixaban | 71 | 14 |
| Mupirocin | Mupirocin | 69 | 46 |
| Novolog Flexpen | Insulin Aspart | 64 | 16 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 63 | 17 |
| Memantine Hcl | Memantine Hcl | 63 | 18 |
| Azithromycin | Azithromycin | 62 | 51 |
| Amoxicillin | Amoxicillin | 60 | 54 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 58 | 11 |
| Prednisone | Prednisone | 58 | 44 |
| Risedronate Sodium | Risedronate Sodium | 57 | 18 |
| Fenofibrate | Fenofibrate,micronized | 56 | 14 |
| Mirtazapine | Mirtazapine | 55 | 13 |
| Levofloxacin | Levofloxacin | 54 | 42 |
| Levetiracetam | Levetiracetam | 50 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 49 | 24 |
| Finasteride | Finasteride | 48 | 16 |
| Nifedipine Er | Nifedipine | 47 | 15 |
| Atenolol | Atenolol | 45 | 12 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 43 | 16 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 43 | 20 |
| Glimepiride | Glimepiride | 43 | 16 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 42 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | suppressed |
| Livalo | Pitavastatin Calcium | 41 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 40 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 40 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 40 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 40 | 18 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 39 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 38 | 12 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 37 | 17 |
| Glipizide Xl | Glipizide | 37 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 37 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 36 | 18 |
| Telmisartan | Telmisartan | 35 | suppressed |
| Aripiprazole | Aripiprazole | 33 | suppressed |
| Xarelto | Rivaroxaban | 33 | suppressed |
| Colchicine | Colchicine | 32 | 16 |
| Donepezil Hcl | Donepezil Hcl | 32 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 32 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 30 | 18 |
| Potassium Chloride | Potassium Chloride | 30 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 29 | 14 |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Bupropion Xl | Bupropion Hcl | 28 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 28 | suppressed |
| Spironolactone | Spironolactone | 28 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 27 | 11 |
| Gemfibrozil | Gemfibrozil | 27 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 27 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 27 | 24 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 25 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 22 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Entresto | Sacubitril/Valsartan | 21 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 20 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Nateglinide | Nateglinide | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 18 | suppressed |
| Febuxostat | Febuxostat | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 14 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 17 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Alogliptin | Alogliptin Benzoate | 15 | suppressed |
| Alprazolam | Alprazolam | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 15 | suppressed |
| Trulance | Plecanatide | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Restasis | Cyclosporine | 14 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 12 | suppressed |
| Entecavir | Entecavir | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Tobramycin | Tobramycin | 12 | suppressed |
| Amantadine | Amantadine Hcl | 11 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 11 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
| Ursodiol | Ursodiol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,982.67 · 99 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, FARXIGA, FREESTYLE LIBRE 3, GVOKE HYPOPEN, INJECTAFER, JARDIANCE, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, PURIFIED CORTROPHIN GEL, QULIPTA, RALDESY, REPATHA, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VERQUVO, VOQUEZNA, Wegovy, XIFAXAN, ZTLido | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error